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Abstract
Background: Risk of normal tissue toxicity limits the amount of thoracic radiation therapy (RT) that can be routinely
prescribed to treat non-small cell lung cancer (NSCLC). An early biomarker of response to thoracic RT may provide
a way to predict eventual toxicities—such as radiation pneumonitis—during treatment, thereby enabling dose
adjustment before the symptomatic onset of late effects. MicroRNAs (miRNAs) were studied as potential serological
biomarkers for thoracic RT. As a first step, we sought to identify miRNAs that correlate with delivered dose and
standard dosimetric factors.
Methods: We performed miRNA profiling of plasma samples obtained from five patients with Stage IIIA NSCLC at
five dose-points each during radical thoracic RT. Candidate miRNAs were then assessed in samples from a separate
cohort of 21 NSCLC patients receiving radical thoracic RT. To identify a cellular source of circulating miRNAs, we
quantified in vitro miRNA expression intracellularly and within secreted exosomes in five NSCLC and stromal cell lines.
Results: miRNA profiling of the discovery cohort identified ten circulating miRNAs that correlated with
delivered RT dose as well as other dosimetric parameters such as lung V20. In the validation cohort,
miR-29a-3p and miR-150-5p were reproducibly shown to decrease with increasing radiation dose. Expression
of miR-29a-3p and miR-150-5p in secreted exosomes decreased with radiation. This was concomitant with
an increase in intracellular levels, suggesting that exosomal export of these miRNAs may be downregulated
in both NSCLC and stromal cells in response to radiation.
Conclusions: miR-29a-3p and miR-150-5p were identified as circulating biomarkers that correlated with
delivered RT dose. miR-150 has been reported to decrease in the circulation of mammals exposed to
radiation while miR-29a has been associated with fibrosis in the human heart, lungs, and kidneys. One may
therefore hypothesize that outlier levels of circulating miR-29a-3p and miR-150-5p may eventually help
predict unexpected responses to radiation therapy, such as toxicity.
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Background
Platinum-based chemotherapy with concurrent radio-
therapy (RT) comprise first-line treatment for locally
advanced NSCLC [1]. However, despite optimal chemo-
radiotherapy, approximately 40 % of patients suffer treat-
ment failure within the irradiated area [2], which
contributes to a dismal 15-25 % survival rate at 5 years
[3, 4]. RTOG 0617 randomized patients to receive 60 vs.
74 Gy to determine whether dose escalation improves
outcomes [5]. Unfortunately outcomes were worse in
the higher dose arm due to increased toxicities and likely
compromised tumor coverage to meet normal tissue
constraints.
Factors that likely contribute to the high rate of locor-
egional failure include our inability to predict which pa-
tients may require dose escalation for local control or
those who can tolerate higher doses to organs-at-risk.
Despite complex variations in anatomic and biological
characteristics between patients and their tumors, RT
regimens have remained relatively uniform. RTOG 0617
established the standard radiation dose of 60 Gy given in
2 Gy daily fractions. In practice, prescriptions range be-
tween 60–70 Gy in 1.8 to 2.0 Gy fractions, depending on
provider preferences and dosimetric constraints related
to radiosensitive structures including the lungs, spinal
cord, esophagus and heart [6]. Despite these constraints,
10–20 % of patients suffer moderate to severe radiation
pneumonitis (RP) following standard treatment [7]. RP
is an inflammatory response of the lungs to radiation
resulting in symptoms of variable severity ranging from
coughing, dyspnea and fever to life-threatening pul-
monary failure. The 10–20 % figure is likely to be
underestimated since the clinical manifestations of RP
are non-specific. In severe cases, the RP-attributed
mortality rate can be as high as 50 % [8].
Recently, microRNAs (miRNAs) have garnered inter-
est as potential biomarkers for a range of biological and
physiological states [9]. miRNAs are small (22–24 nu-
cleotide), non-coding RNAs that decrease the expression
levels of as many as 60 % of all coding sequences in the
human genome [10, 11]. Circulating miRNAs are attract-
ive as biomarkers of tumor radiation response and
normal-tissue toxicity. They constitute the major frac-
tion of small nucleic acids found in circulation, and des-
pite high concentrations of RNA-degrading enzymes,
circulating miRNA expression levels have been reprodu-
cibly measured to be stable [9]. They are also readily
accessible through non-invasive blood testing. miRNA
expression has been shown to specifically change in
murine serum following whole body radiation [12]. In
humans, miRNA expression in peripheral blood cells has
been used to accurately distinguish pre- and post-
radiation states [13]. While the mechanism underlying
these changes remains unclear, miRNAs are involved in
regulating the DNA damage response, making them es-
pecially relevant in the context of RT for NSCLC [14].
Despite being widely reported as potential biomarkers,
the origins of circulating miRNAs are not fully under-
stood. The majority of circulating miRNAs in plasma are
found within exosomes, which help protect miRNAs
from degradation [15]. Exosomes are small (50-80 nm)
membrane vesicles of endocytic origin that are formed
by the involution of endosomes into multivesicular bod-
ies (MVB) [16]. Mature MVBs subsequently fuse with
the plasma membrane to release exosomes from the cell
in an orchestrated manner distinct from exocytosis.
Exosomes containing miRNAs have been shown to me-
diate intercellular communication in processes such as
antigen presentation and malignant transformation in
EBV-associated lymphomas [17, 18].
In this study, we hypothesized that miRNA expression
in the peripheral circulation may serve as biomarkers of
radiation exposure during thoracic RT for NSCLC pa-
tients. We also investigated the potential cellular source
of circulating miRNAs by measuring miRNA expression
in exosomes isolated from conditioned media of cultured
cells. These miRNAs may correspond to normal tissue
and/or tumor response, allowing prediction of acute and
delayed injury to these organs. With validation, such
biomarkers have the potential to guide adaptive RT for
NSCLC patients based on their biologic responses to
radiation.
Methods
miRNA profiling and validation
Five plasma samples from each of five patients with
Stage IIIA NSCLC undergoing radical chemoradiother-
apy (profiling cohort) were collected before—and at ap-
proximately two-week intervals during—RT (Table 1).
All patients received six MV photons and either 3D con-
formal or intensity modulated RT. 10 mL of blood were
collected in spray coated potassium EDTA Vacutainer
tubes (Fisher Scientific). Whole blood was transferred to
15 mL conical tubes (Falcon) and immediately spun at
2000 × g for 15 min at 4 °C. The resulting platelet-
depleted plasma was aspirated and aliquoted into 500 μl
volumes and stored in 1.5 mL cryovials (Corning) at -80 °C.
Samples were comprehensively profiled for known human
miRNAs (~1900) using Exiqon miRCURY LNA Universal
RT microRNA PCR Human Panel I + II arrays (Exiqon,
Copenhagen). Array data are included in the (Additional
file 1: Table S1). Candidate miRNAs whose levels signifi-
cantly correlated with RT dose, lung V5 and V20 (percent
of lung volume receiving doses of at least 5 and 20 Gy, re-
spectively), mean lung dose and mean esophagus dose were
identified. miRNA candidates identified in the screen were
validated using samples from an additional 21 NSCLC pa-
tients (validation cohort), collected before—and at 20 Gy
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intervals during—RT. Patients in the validation cohort
had similar disease characteristics and treatment regi-
mens (Table 2). One sample each from the 0 Gy and
40 Gy groups as well as two from the 20 Gy group
had undetectable levels of miRNAs. Since we had no
way of verifying whether this was due to technical
error, sample storage or actual decrease of miRNA
below the detection threshold we did not perform
missing data imputation.
Total RNA was isolated from 200 μL plasma samples
using Exiqon miRCURY Biofluids Total RNA Isolation
kits. RNA samples measurements quality control data
are included in the (Additional file 1: Table S2). cDNA
synthesis was performed using Exiqon Universal cDNA
first-strand synthesis kits. Quantitative real-time PCR
(Q-PCR) was performed using the Exiqon SYBR Green
system in a 96-well format. All LNA primers were or-
dered from Exiqon and added at 250 nM final concen-
tration. Q-PCR dCp data for the validation cohort are
included in the (Additional file 1: Table S3).
For the profiling cohort samples, UniSp2, UniSp4, and
UniSp5 were used as RNA isolation spike-in controls.
UniSp6 was used as cDNA synthesis spike-in controls.
Additionally, the DNA spike-in UniSp3 was added. In
the validation cohort samples, UniSp3 and UniSp6 were
used as spike-in controls. In all samples, spike-in con-
trols were assayed at steady levels. The difference in
miR-451 and miR-23a expression in plasma samples was
used to assess hemolysis, with a cutoff of value of greater
than eight [19].
Table 1 Patient characteristics of profiling cohort
Patient Age/Gender Diagnosis Indication/Type of treatment Chemotherapy RT dose
2468 76/F IIIA SCC definitive KT 60.0 Gy
2510 61/F IIIA ADENO definitive EP 66.0 Gy
2526 60/M IIIA ADENO neoadjuvant EP 54.0 Gy
2534 60/F IIIA SCC definitive EP 66.0 Gy
2561 76/M IIIA ADENO definitive KT 66.0 Gy
Abbreviations: SCC squamous cell carcinoma, ADENO adenocarcinoma, KT carboplatin/paclitaxel, EP, etoposide/cisplatin
Table 2 Patient characteristics of validation cohort
Patient Age/Gender Diagnosis Indication/Type of treatment Chemotherapy RT dose
AE1 58/F IIA SCC recurrence/adjuvant PN 70.0 Gy
BE1 68/M IIIA SCC definitive KG 66.0 Gy
CG1 55/M IIA SCC R2/adjuvant PN 68.0 Gy
DW1 59/F IIB SCC R1/adjuvant PN 68.0 Gy
FL1 76/M IIIA SCC definitive PG 66.0 Gy
GH1 62/F IIIB SCC definitive PN 66.0 Gy
GK1 67/M IIIB SCC definitive KN 66.0 Gy
GW1 61/M IIIA SCC definitive PG 66.0 Gy
KA1 64/F IIIB ADENO definitive PN 58.0 Gy
KA2 64/M IIB SCC R1/adjuvant PN 60.0 Gy
KI1 68/F IIIA SCC R1/adjuvant KN 60.0 Gy
KM1 67/M IIIA SCC R1/adjuvant PN 60.0 Gy
LJ1 77 M IIIA SCC R1/adjuvant No chemo 56.0 Gy
MS1 70/M IIIA SCC R1/adjuvant KN 66.0 Gy
PB1 60/M IIIA NOS definitive PG 64.0 Gy
PI1 56/F IIIB ADENO definitive PN 66.0 Gy
SB1 55/M IIIA SCC R1/adjuvant PN 69.3 Gy
SJ1 55/M IIB NOS R1/adjuvant PN 66.0 Gy
SW1 62/M IIIB ADENO definitive PN 66.0 Gy
WJ1 73/M IIIA ADENO definitive PG 60.0 Gy
ZA1 78/M IIIA ADENO definitive KG 66.0 Gy
Abbreviations: SCC squamous cell carcinoma, ADENO adenocarcinoma, NOS not otherwise specified, R1 positive microscopic margins, R2 positive gross margins, PN
cisplatin/vinorelbine, KG carboplatin/gemcitabine, PG cisplatin/gemcitabine, KN carboplatin/vinorelbine
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Measurement of radiation-responsive plasma miRNAs in
cell lines and conditioned media
Human NSCLC cell lines NCI-H460 (large cell lung car-
cinoma), A549 (type II alveolar cell carcinoma) and
NCI-H1299 (lung adenocarcinoma) were gifts from Dr.
Matthew Meyerson. These lines were authenticated by
Short Tandem Repeat (STR) profiling (ATCC). MRC5
(embryonic lung fibroblasts) and IMR90 (embryonic
lung fibroblasts) were obtained directly from ATCC for
this work and used in early passage [20–24]. Cells were
grown in 10 cm tissue culture plates. NSCLC cells were
cultured in Roswell Park Memorial Institute (RPMI)
1640 (Life Technologies, Carlsbad, USA) media. MRC5
and IMR90 cells were cultured in Eagle’s Modified Es-
sential Media (ATCC, Manassas, USA). Media were sup-
plemented with 10 % fetal bovine serum (FBS, Sigma).
The same batch of FBS was used for all in-vitro experi-
ments, which was profiled for miRNAs of interest and
background normalization (Additional file 1: Figure S1).
For measurement of intracellular miRNA expression,
cells were transferred to 6-well tissue-culture plates
(Thermo Fisher, Waltham, USA) at a density of 105 cells
per well and allowed to reach log-phase growth in 48 h.
Samples (n = 6 per group) were then irradiated with
2 Gy per day for 1, 2 or 3 days at a dose rate of 83 cGy
per minute (2, 4 or 6 Gy total dose) using a Gammacell
40 Exactor (Best Theratronics, Ottawa, Canada). Cells
were trypsinized and harvested 2 h after irradiation.
Total RNA was immediately isolated from cell pellets
using Exiqon miRCURY Plant and Cells Total RNA Iso-
lation kits. RNA samples measurements quality control
data are included in the (Additional file 1: Table S2).
For measurement of extracellular miRNA expression
in conditioned media, cells were transferred to 15 cm
tissue-culture plates (Thermofisher) at a density of 106
cells per plate and allowed to reach log-phase growth in
48 h. Samples (n = 3 per group) were then irradiated at
2 Gy per day for 1 or 3 days (2 or 6 Gy total dose). Fresh
media was added one hour prior to radiation on day 1
and media was not changed subsequently. After days 1
and 3, 10 mL conditioned media was collected from
each plate 2 h after irradiation. Exosomes were isolated
and purified using a solvent-exchange exosome isolation
kit (Exiqon) before total RNA was isolated with Plant
and Cells Total RNA Isolation kits. Isolation of exo-
somes was confirmed by Western blotting for Tsg101, a
protein involved in multivesicular biogenesis [15, 25]
(Additional file 1: Figure S2).
cDNA synthesis was performed using Exiqon universal
cDNA first‐strand synthesis kits by adding 100 ng total
RNA for intracellular samples. As established by Blondal
et al., 6.5 μL total RNA was added for cDNA synthesis
for exosome samples [19]. Quantitative RT‐PCR was
performed using Exiqon SYBR Green master mix. All
LNA primers except miR‐150‐5p were ordered from Exi-
qon and added at 250 nM final concentration. Q‐PCR
was performed using an AB‐7500 thermocycler with a
detection cutoff of 40 cycles. For miR‐150‐5p, the
Qiagen miSCRIPT SYBR Green primer assay was used,
reverse transcription (RT‐PCR) was performed using the
miSCRIPT RT Kit (Qiagen) and Q‐PCR was performed
using the miSCRIPT SYBR Green Kit (Qiagen), follow-
ing manufacturer’s protocols.
For normalization of intracellular miRNA expression,
the snRNA sequence U6 and miR-103a have been estab-
lished as normalizers for quantification of intracellular
miRNAs and were measured in addition to the two most
stably expressed miRNAs from the initial screen, miR-
let-7d and miR-16-2-3p [26]. miR-let-7a-5p has been
shown to perform well as a normalizer for miRNA quan-
tification of exosomes derived from cell culture and was
measured to potentially supplement miR-let-7d and
miR-16-2-3p [27]. NormFinder was used to find the
most stably expressed pair, relative to miR-29a and miR-
150, for normalization. Stability values are included in
the (Additional file 1: Table S4).
Cell viability was determined using the trypan blue
dye exclusion method, using a standard protocol
[28]. Cell proliferation was assessed by manually
counting adherent cells, averaged over five random
high-powered fields (40×).
Statistical methods
In the profiling experiment, miRNA expression data
were normalized toward the average expression of miR-
NAs detectable in all samples. Using those miRNAs for
normalization, we calculated dCp values by using the
formula “dCp = Average Cp – miRNA of interest Cp.”
Thus, higher scores represent higher expression levels.
For in vitro experiments, fold changes of relative expres-
sion were calculated using the ΔΔCt method [29].
In the profiling cohort, we used analysis of variance
(ANOVA) to identify miRNAs whose expression dif-
fered significantly depending on radiation dose. The
Benjamini-Hochberg step-up method was used to ad-
just significance values for multiple comparisons
testing [30]. miRNAs that showed significance in
ANOVA were selected for the validation experi-
ments. miR-let-7d, miR-324, miR-16-2-3p and miR-
126 were used as normalizers based upon their uni-
versal expression in all samples and high stability in
the profiling dataset, as assessed by Normfinder [31].
Analysis in the validation cohort was performed using
63 samples from 21 patients treated for locally-advanced
NSCLC to verify whether the observed differences repli-
cate in that cohort as well. Given the larger number of
patients and repeated measures at prespecified time-
points we were able to use a mixed model approach that
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evaluated the effect of the timepoint (fixed effect) and
intraindividual differences in radiation response patterns
(random effect). We performed pairwise comparisons
between the baseline, 20 Gy and 40 Gy timepoints using
the Newman-Keuls test.
We subsequently evaluated correlations between miRNA
and dosimetry parameters to determine the pattern of
changes of miRNAs differentially expressed in the profiling
experiment. Pearson’s correlation was used to evaluate the
direction and strength of such correlations.
For in-vitro data, we used Student’s t-test to compare
miRNA expression levels between groups. In all cases,
we assumed p levels < 0.05 to be statistically significant.
Results
Profiling of patient blood samples identifies two
circulating miRNAs that inversely correlate with RT dose
Of 752 miRNAs measured in at least one sample in the
profiling cohort, 124 were universally detected in all 25
samples. Four samples were excluded at pre-processing
due to hemolysis. Ten miRNAs differed significantly
(adjusted p < 0.05) depending on the received RT dose
(Fig. 1). Of these ten miRNAs, miR-150-5p (p = 0.036)
and miR-29a-3p (p = 0.032) (hereafter miR-150 and miR-
29a) were shown to differ significantly depending on the
received RT dose in the validation cohort (Fig. 2). The
remaining eight candidate miRNAs identified in the pro-
filing cohort did not reach statistical significance in the
validation samples (Additional file 1: Table S5). As in the
profiling cohort, circulating levels of miR-29a and miR-
150 decreased with increasing RT dose. Despite a high
variability of miRNA expression levels, the patterns
remained convergent at intraindividual levels, confirm-
ing their specific reaction to RT. miR-29a and miR-150
also significantly correlated with clinically relevant dosi-
metric parameters: lung V5 and V20, mean lung dose
and mean esophagus dose (Table 3).
Intracellular levels of miR-29a-3p and miR-150-5p increase
after irradiation in NSCLC cells and in lung fibroblasts
In all three tested NSCLC cell lines, NCI-H460, A549
and NCI-H1299, radiation increased the intracellular ex-
pression of miR-29a and miR-150 as early as 2 h after ir-
radiation (Fig. 3). This difference persisted with each
fraction of radiation for up to 3 days of treatment. The
same pattern of increase was also observed in two non-
cancer cell lines, MRC5 and IMR90. For miR-29a, the
relative increase in intracellular expression peaked after
the second fraction of radiation, e.g. in H1299 cells
where expression returned to baseline after the third
fraction. For miR-150, the relative increase in intracellu-
lar expression did not express a clear temporal trend, al-
though expression was typically highest after the first
fraction of radiation. miR-let-7d, miR-16-2-3p and miR-
103 demonstrated the highest Normfinder stability and
were used for normalization. In concordance with recent
studies, U6 routinely demonstrated low stability across
groups, and was not used as a normalizer [26].
miR-29a-3p and miR-150-5p levels are lower in exosomes
secreted into the conditioned media of cells
miR-29a and miR-150 levels were lower in exosomes
purified from conditioned media of irradiated NCI-
H460, A549 and NCI- H1299 cells compared to unirra-
diated control (Fig. 4). This difference persisted with
each fraction of radiation for up to 3 days of treatment.
Exosomal miR-29a and miR-150 were also lower for
irradiated MRC5 and IMR90 cells (Fig. 4). At a 2 Gy
-3.0 0.0 3.0
miRNA
adjusted
p-value Median Relative Fold Change
miR-29a-3p
miR-150-5p
miR-101-5p
miR-342-3p
miR-30d-5p
miR-320a
miR-142-3p
miR-191-5p
miR-125b-5p
miR-15b-5p
0.0037
0.0083
0.014
0.017
0.021
0.025
0.029
0.035
0.045
0.048
0.47 (down)
0.16 (down)
0.56 (down)
3.36 (up)
1.34 (up)
1.13 (up)
0.46 (down)
2.06 (up)
0.65 (down)
1.77 (up)
Fig. 1 Heatmap of statistically significant miRNAs from microarray profiling of plasma samples obtained during RT. Of 124 universally expressed
miRNAs, 10 were significantly correlated with RT dose. Five miRNAs decreased in expression in circulation with increasing radiation dose while
five increased in expression. The median relative fold changes in miRNA expression among all five patients are shown. ANOVA adjusted p-values
were calculated with the Benjamini-Hochberg procedure and represent false discovery rates
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fractional dose, radiation treatment abrogated prolifera-
tion in all cell lines, but did not significantly induce cell
death (Additional file 1: Figure S3). miR-let-7a, miR-let-
7d and miR-16-2-3p demonstrated high Normfinder sta-
bility and were used for normalization.
Discussion
The Quantitative Analyses of Normal Tissue Effects in
the Clinic (QUANTEC) study delineated dosimetric pa-
rameters, such as mean lung dose (MLD) and lung V20
that predict RP and other normal-tissue toxicities [6].
Unfortunately, the meta-analysis failed to identify any re-
liable threshold for RP. Indeed, rates of RP varied widely
at any particular MLD or lung Vx. Thus, contemporary
management is informed by institutional and protocol
guidelines for these dosimetric parameters, based on
what is felt to be acceptable risk to the average patient.
In principle however, even if a dosimetric threshold
could be reliably established, it would only provide a
population-based estimator of RP risk. What would be
p = 0.039 p = 0.75
p = 0.032
0 Gy 20 Gy 40 Gy
Cumulative Radiation Dose at Collection (Gy)
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
-0.5
-1.0
-1.5
-2.0
0 Gy 20 Gy 40 Gy
Cumulative Radiation Dose at Collection (Gy)
p = 0.021 p = 0.54
p = 0.036
6
5
4
3
2
1
0
-1
-2
A
B
Fig. 2 Validation of miR-29a-3p and miR-150-5p. (a) miR-29a-3p and (b) miR-150-5p expression significantly decreased in the circulation during
the course of thoracic RT in the validation cohort (overall p = 0.032 and 0.036, respectively). P-values displayed are post-hoc comparisons between
0 and 20 Gy, 20 and 40 Gy, and 0 and 40 Gy. Higher dCp scores represent higher expression levels. Error bars represent standard deviation
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more clinically useful would be a constitutive biomarker
that dynamically estimates risk of RP over the course of
radiation therapy. Whereas dosimetry is a proxy, we
wish to interrogate the biology itself.
Recent efforts have focused on potential biochemical
markers in the lung [32–35]. Anscher and colleagues
attempted prospective dose-escalation in lung cancer pa-
tients whose serum TGF-β1 levels had renormalized at the
end of standard-dose RT [36]. Unfortunately, many patients
in the TGF-β1 -guided dose-escalation arm still experienced
RP despite having TGF-β1 levels that predicted low risk of
RP. Chen and colleagues found that circulating levels of IL-
6 were higher after RT in a small group of patients who
developed mild RP [37]. However, the sensitivity and speci-
ficity of IL-6 to retrospectively predict RP was limited to
78 % and 40 %, respectively [38]. Stenmark et al. attempted
to combine dosimetric parameters with inflammatory cyto-
kines in order to improve the prediction of RP [39]. They
were able to slightly improve RP sensitivity (80 %), but still
reported low specificity (60 %). These inflammatory factors
may be limited as serological biomarkers due to the short
half-lives of proteins in serum [40]. Circulating miRNAs
are remarkably stable in serum, and may therefore offer
better performance as biomarkers.
In this study, we identified two miRNAs that decreased in
circulation with thoracic RT in patients with locally-
advanced NSCLC. This two-miRNA signal remained signifi-
cant despite inter-patient variability in our relatively small
sample size. This may imply that these miRNAs are robust
biomarkers, but does not preclude others that may become
significant with increased statistical power. Due to institu-
tional differences in treatment protocols, 10 of 21 patients
in the validation cohort received radiation in the adjuvant
setting while the remaining underwent definitive radical che-
moradiotherapy. However, all patients in the profiling cohort
underwent definitive radical chemoradiotherapy. This het-
erogeneity in the validation cohort may have altered the rate
of change in lung or tumor-specific miRNAs, as we would
expect irradiated volumes to be different in the adjuvant as
compared to neoadjuvant setting. This may explain why
only the two most significant signals identified in the profil-
ing cohort remained significant in the validation cohort.
To determine the potential source of this circulating
miRNA signal, we measured the expression of significant
miRNAs intracellularly and within exosomes recovered
from NSCLC and stromal cell culture. In harmony with
both our screening and validation data of miRNAs found
in circulation, radiation significantly diminished miR-29a
and miR-150 accumulation in exosomes secreted into
conditioned media. Interestingly, miRNA expression
increased intracellularly with radiation. These patterns-
while experimentally separate-suggest that the decrease
in miR-29a and miR-150 levels in circulation may be a
regulated process, rather than simply a reflection of
decreasing intracellular miRNA expression. Both tumor
and non-tumor cells may be downregulating the export
of miRNAs, via decreased exosome secretion or
decreased miRNA loading into secreted exosomes, lead-
ing to an intracellular buildup of miRNAs. Either mech-
anism would be an interesting effect of radiation worth
further investigation. The decrease in relative exosomal
export of miR-29a and miR-150 appears to hold for both
NSCLC cells and lung stroma cells, although the miRNA
expression patterns of other cell types found in the lung
(e.g. lymphocytes and endothelial cells) were not
measured. A limitation of these in vitro data is that
intracellular and exosomal miRNA expression was not
measured in the same experiment. Thus, the relationship
between intracellular miRNA expression and exosomal
miRNA expression is indirect. However, with the excep-
tion of larger culture plates to allow for the collection of
sufficient conditioned media for exosome isolation, all
other experimental conditions were identical.
Whether miRNAs circulate freely, are associated with ri-
bonucleoprotein complexes or are encapsulated within
exosomes remains unclear [15, 41, 42]. Notably, Arroyo
et al. showed that miR-let-7a, miR-92a, and miR-142-3p
circulate predominantly complexed to Argonaute-2 pro-
tein (a member of the RNA-induced silencing complex).
Gallo et al. however subsequently found that these same
Table 3 Correlation of miRNA expression and dosimetric parameters
Of 10 miRNAs significantly correlating with total dose, seven also significantly correlated with lung V5 (percent of lung volume receiving 5 Gy or greater), lung
V20 (percent of lung volume receiving 20 Gy or higher), mean lung dose (MLD) and/or mean esophagus dose. Pearson correlation coefficient (r) and p-values are
reported. Significant values are indicated in red with asterisks
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miRNAs, as well as all miRNAs they tested in human
serum, were much more enriched within purified exo-
somes. To our knowledge, no prior study specifically
showed that circulating miR-29a or miR-150 is exosome
associated. However we observed that these miRNAs had
Ct values less than 35 cycles in exosome isolates but were
undetectable in exosome-depleted samples (>40 cycles).
Notably, we observed that a 2 Gy fraction size was
sub-lethal, whereas a lysis model of miRNA release
would require significant cell death (Additional file 1:
Figure S3). A conceivable alternate interpretation of the
exosome expression pattern may be that radiation sim-
ply decreases cell proliferation, thereby leading to an
apparent decrease in exosomal miRNA. This is unlikely
because the significant relative decrease happens as early
as 2 h after radiation, when there is a negligible differ-
ence in cell proliferation between irradiated and control
samples.
Our results concur with previous studies by Templin
and colleagues showing that miR-150 decreases in the
blood of mice exposed to whole body radiation [12]. Our
laboratory has also found that miR-150 decreases in the
circulation of mice exposed specifically to thoracic radi-
ation (unpublished data). miR-150 has been identified as
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Fig. 4 Exosomal expression of (a-e) miR-29a and (f-j) miR-150. Both
miRNAs decreased in both NSCLC and stromal cell lines after 1 or
3 days of 2 Gy fractions. Error bars represent standard deviation
for n = 3 samples (*p < 0.05, ***p < 0.001)
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Fig. 3 Intracellular expression of miR-29a and miR-150p. (a-e) miR-29a
and (f-j) miR-150 levels increased with radiation in both NSCLC and
stromal cell lines after 1, 2 or 3 days of 2 Gy fractions. Error bars
represent standard deviation for n = 4 samples (*p < 0.05, ***p < 0.001)
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an important promotor of inflammation via its regula-
tion of MYB, an evolutionarily conserved regulator of
hematopoiesis [43, 44]. Adams and colleagues demon-
strated that over-expression of miR-150 impaired bone
marrow reconstitution after hematopoietic ablation with
5-flourouracil [45]. In the context of circulating miR-
NAs, miR-150 may be a general marker of a leukocyte-
driven inflammation in mammals exposed to radiation.
To our knowledge, there has been no prior study linking
miR-29a to radiation exposure. It is well described as an
inhibitor of extracellular matrix (ECM) remodeling via
its binding of 21 downstream proteins in the TGF-β/
Smad3 pathway [46–48]. Reduction in miR-29a levels
has been associated with bleomycin-induced lung fibro-
sis [47], ischemia-related myocardial fibrosis [46], and
hypertension-associated renal fibrosis [48]. The decrease
in circulating levels of miR-29a after thoracic radiation
may indicate a pro-fibrotic state. Alternatively, the con-
comitant increase in intracellular miR-29a may be an
adaptive response to radiation exposure. This has direct
implications for miR-29a being a specific biomarker for
predicting radiation pneumonitis. Indeed, miR-29a had
higher statistical correlation with radiation dose com-
pared to miR-150 in patients undergoing thoracic RT.
Data from the Cancer Genome Atlas also reveals that
miR-29a is expressed at much higher levels in both
NSCLC tumors and normal lung tissue compared to
miR-150 (Additional file 1: Figure S4).
Conclusions
We show from an unbiased screen that miR-29a and miR-
150 decrease in the circulation of NSCLC patients under-
going thoracic RT. Furthermore, this miRNA signal may
originate—at least in part—from intracellular accumula-
tion and concomitant reduction in exosome export from
NSCLC and stromal cells. While miR-150 is likely a gen-
eral biomarker of any tissue exposed to radiation, the re-
duction in circulating miR-29a may reflect a pro-fibrotic
or adaptive state in the lung specifically. Patients whose
levels of miR-29a decrease significantly more (in a pro-
fibrosis model), or less (in an adaptive model), compared
to average may be at higher risk for RP. Likewise, these
differential expression patterns may reflect biological
tumor response (or resistance) to radiation. Future studies
will collect serum samples from a large number of NSCLC
patients receiving RT in order to establish whether outlier
trends in miR-29a and/or miR-150 corresponds to RP risk
or tumor response. Establishing these miRNAs of interest
as biomarkers for toxicity and/or tumor response may
greatly facilitate patient-specific tailoring of RT.
Ethics approval and consent to participate
All patients in the screening cohort gave informed con-
sent per Dana-Farber/Harvard Cancer Center Protocol
02-180. All procedures were performed in accordance
with local ethical standards and the Helsinki Declaration
as revised in 2000.
Consent for publication
Not applicable.
Availability of data and materials
Raw miRNA profiling data are available for download as
Supplementary Material.
Additional file
Additional file 1: Table S1. Profiling cohort data. Table S2. RNA
samples measurements. Table S3. Validation cohort Q‐PCR data.
Table S4. NormFinder results. Table S5. Validation of miRNAs candidates.
Figure S1. Background expression of miRNAs. Figure S2. Exosome
isolation. Figure S3. Viability vs. IR status. Figure S4. miRNA expression
in NSCLC and lung samples. (PDF 470 kb)
Abbreviations
ANOVA: analysis of variance; FBS: fetal bovine serum; miRNA: microRNA;
MLD: mean lung dose; MVB: multivesicular body; NSCLC: non-small cell lung
cancer; RT: radiotherapy.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TKD performed the majority of laboratory experiments and drafted the
manuscript. WF performed the statistical analyses and revised the
manuscript. JCh-F provided validation patient samples and clinical data. SSA,
CO and PVD performed additional laboratory experiments. ADD, DC and DK
conceptualized and oversaw the project and revised the manuscript.
All authors read and approved the final manuscript.
Funding
TKD received a fellowship from the Howard Hughes Medical Institute. JCh-F
received support from the National Science Center grant no. 2012/05/N/
NZ5/02621 and Foundation for Polish Science grant no. 127/UD/SKILLS/2015.
DC and DK received grant funding from the Department of Radiation Oncology
at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital. DK is
supported by LUNGevity Foundation Career Development Award 2013-02 and
NIH/NCI K08CA172354.
Author details
1Harvard Medical School, 25 Shattuck St, Boston, MA 02115, USA.
2Department of Radiation Oncology, Dana-Farber Cancer Institute, 450
Brookline Ave, Boston, MA 02215, USA. 3Department of Biostatistics and
Translational Medicine, Medical University of Łódź, Al. Kościuszki 4, 90-419
Łódź, Poland. 4Department of Radiation Oncology, Medical University of
Łódź, Al. Kościuszki 4, 90-419 Łódź, Poland. 5Center for DNA Damage and
Repair, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215,
USA. 6Department of Radiation Oncology, Brigham and Women’s Hospital,
75 Francis St, Boston, MA 02115, USA.
Received: 19 November 2015 Accepted: 14 April 2016
References
1. Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA,
Diekemper R, Detterbeck FC, Arenberg DA. CHEST Supplement. Chest. 2013;
143(5):e314S–40.
2. Garg S, Gielda BT, Kiel K, Turian JV, Fidler MJ, Batus M, Bonomi P, Sher DJ.
Patterns of locoregional failure in stage III non-small cell lung cancer treated
with definitive chemoradiation therapy. Pract Radiat Oncol. 2014;4(5):342–8.
Dinh et al. Radiation Oncology  (2016) 11:61 Page 9 of 11
3. van Meerbeeck JP, Kramer GWPM, Van Schil PEY, Legrand C, Smit EF,
Schramel F, Tjan-Heijnen VC, Biesma B, Debruyne C, van Zandwijk N, et al.
Randomized Controlled Trial of Resection Versus Radiotherapy After
Induction Chemotherapy in Stage IIIA-N2 Non–Small-Cell Lung Cancer. J
Natl Cancer Inst. 2007;99(6):442–50.
4. Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, Chen Y,
Livingston RB, Feins RH, Gandara DR. Radiotherapy plus chemotherapy with
or without surgical resection for stage III non-small-cell lung cancer: a phase
III randomised controlled trial. Lancet. 2009;374(9687):379–86.
5. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart
J, Hu C, Forster K, Magliocco A, et al. Standard-dose versus high-dose
conformal radiotherapy with concurrent and consolidation carboplatin
plus paclitaxel with or without cetuximab for patients with stage IIIA or
IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two
factorial phase 3 study. Lancet Oncol. 2015;16(2):187–99.
6. Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, El Naqa I,
Hubbs JL, Lebesque JV, Timmerman RD, et al. Radiation dose-volume effects
in the lung. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S70–6.
7. Mehta V. Radiation pneumonitis and pulmonary fibrosis in non–small-cell
lung cancer: Pulmonary function, prediction, and prevention. Int J Radiat
Oncol Biol Phys. 2005;63(1):5–24.
8. Jenkins P, D’Amico K, Benstead K, Elyan S. Radiation pneumonitis
following treatment of non–small-cell lung cancer with continuous
hyperfractionated accelerated radiotherapy (CHART). Int J Radiat Oncol
Biol Phys. 2003;56(2):360–6.
9. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X.
Characterization of microRNAs in serum: a novel class of biomarkers for
diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006.
10. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell.
2004;116(2):281–97.
11. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell.
2009;136(2):215–33.
12. Templin T, Amundson SA, Brenner DJ, Smilenov LB. Whole mouse blood
microRNA as biomarkers for exposure to &b. gamma;-rays and 56Fe ions. Int
J Radiat Biol. 2011;87(7):653–62.
13. Templin T, Paul S, Amundson SA, Young EF, Barker CA, Wolden SL, Smilenov
LB. Radiation-induced micro-RNA expression changes in peripheral blood
cells of radiotherapy patients. Int J Radiat Oncol Biol Phys. 2011;80(2):549–
57.
14. Chowdhury D, Choi YE, Brault ME. Charity begins at home: non-coding RNA
functions in DNA repair. Nat Rev Mol Cell Biol. 2013;14(3):181–9.
15. Gallo A, Tandon M, Alevizos I, Illei GG. The majority of microRNAs
detectable in serum and saliva is concentrated in exosomes. PLoS ONE.
2012;7(3):e30679.
16. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO.
Exosome-mediated transfer of mRNAs and microRNAs is a novel
mechanism of genetic exchange between cells. Nat Cell Biol.
2007;9(6):654–9.
17. Mittelbrunn M, Gutiérrez-Vázquez C, Villarroya-Beltri C, González S, Sánchez-
Cabo F, González MÁ, Bernad A, Sánchez-Madrid F. Unidirectional transfer of
microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat
Commun. 2011;2:282.
18. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA,
Hopmans ES, Lindenberg JL, de Gruijl TD, Würdinger T, Middeldorp JM.
Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci U S A.
2010;107(14):6328–33.
19. Blondal T, Nielsen SJ, Baker A, Andreasen D, Mouritzen P, Teilum MW,
Dahlsveen IK. Assessing sample and miRNA profile quality in serum and
plasma or other biofluids. Methods. 2013;59(1):S1–6.
20. Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW,
Zweig MH, Minna JD. Establishment and identification of small cell lung
cancer cell lines having classic and variant features. Cancer Res. 1985;45(6):
2913–23.
21. Lieber M, Todaro G, Smith B, Szakal A, Nelson‐Rees W. A continuous tumor‐
cell line from a human lung carcinoma with properties of type II alveolar
epithelial cells. Int J Cancer. 1976;17(1):62–70.
22. Phelps RM, Johnson BE, Ihde DC, Gazdar AF, Carbone DP, McClintock PR,
Linnoila RI, Matthews MJ, Bunn PA, Carney D. NCI‐navy medical oncology
branch cell line data base. J Cell Biochem. 1996;63(S24):32–91.
23. Jacobs JP, Jones CM, Baille JP. Characteristics of a human diploid cell
designated MRC-5. Nature. 1970;227(5254):168–70.
24. Nichols W, Murphy D, Cristofalo V, Toji L, Greene A, Dwight S.
Characterization of a new human diploid cell strain, IMR-90. Science.
1977;196(4285):60–3.
25. Eldh M, Lötvall J, Malmhäll C, Ekström K. Importance of RNA isolation
methods for analysis of exosomal RNA: evaluation of different methods. Mol
Immunol. 2012;50(4):278–86.
26. Peltier HJ, Latham GJ. Normalization of microRNA expression levels in
quantitative RT-PCR assays: Identification of suitable reference RNA targets
in normal and cancerous human solid tissues. RNA. 2008;14(5):844–52.
27. Li Y, Zhang L, Liu F, Xiang G, Jiang D, Pu X. Identification of endogenous
controls for analyzing serum exosomal miRNA in patients with hepatitis B or
hepatocellular carcinoma. Dis Markers. 2015;2015:893594.
28. Strober W. Trypan blue exclusion test of cell viability. Curr Protoc Immunol.
2001;A:3B. 1-A. 3B. 2.
29. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative
C(T) method. Nat Protoc. 2008;3(6):1101–8.
30. Benjamini Y, Hochberg Y. Controlling the false discovery rate; a practical
and powerful approach to multiple testing. J R Stat Soc Series B Stat
Methodol 1995:289–300.
31. Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative
reverse transcription-PCR data: a model-based variance estimation approach
to identify genes suited for normalization, applied to bladder and colon
cancer data sets. Cancer Res. 2004;64(15):5245–50.
32. Bentzen SM, Parliament M, Deasy JO, Dicker A, Curran WJ, Williams JP,
Rosenstein BS. Biomarkers and surrogate endpoints for normal-tissue effects
of radiation therapy: the importance of dose–volume effects. Int J Radiat
Oncol Biol Phys. 2010;76(3):S145–50.
33. Li C, Wilson PB, Levine E, Barber J, Stewart AL, Kumar S. TGF‐β1 levels in
pre‐treatment plasma identify breast cancer patients at risk of developing
post‐radiotherapy fibrosis. Int J Cancer. 1999;84(2):155–9.
34. Anscher MS, Kong F-M, Andrews K, Clough R, Marks LB, Bentel G, Jirtle RL.
Plasma transforming growth factor β1 as a predictor of radiation
pneumonitis. Int J Radiat Oncol Biol Phys. 1998;41(5):1029–35.
35. Zhao L, Wang L, Ji W, Wang X, Zhu X, Hayman JA, Kalemkerian GP, Yang W,
Brenner D, Lawrence TS. Elevation of plasma TGF-β1 during radiation
therapy predicts radiation-induced lung toxicity in patients with non-small-
cell lung cancer: a combined analysis from Beijing and Michigan. Int J
Radiat Oncol Biol Phys. 2009;74(5):1385–90.
36. Anscher MS, Marks LB, Shafman TD, Clough R, Huang H, Tisch A, Munley M,
Herndon II JE, Garst J, Crawford J. Risk of long-term complications after TFG-
β1–guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol
Phys. 2003;56(4):988–95.
37. Chen Y, Rubin P, Williams J, Hernady E, Smudzin T, Okunieff P.
Circulating IL-6 as a predictor of radiation pneumonitis. Int J Radiat
Oncol Biol Phys. 2001;49(3):641–8.
38. Chen Y, Hyrien O, Williams J, Okunieff P, Smudzin T, Rubin P. Interleukin (IL)-1A
and IL-6: applications to the predictive diagnostic testing of radiation
pneumonitis. Int J Radiat Oncol Biol Phys. 2005;62(1):260–6.
39. Stenmark MH, Cai X-W, Shedden K, Hayman JA, Yuan S, Ritter T, Ten Haken
RK, Lawrence TS. Combining physical and biologic parameters to predict
radiation-induced lung toxicity in patients with non-small-cell lung cancer
treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys. 2012;
84(2):e217–22.
40. Tang L, Persky AM, Hochhaus G, Meibohm B. Pharmacokinetic aspects of
biotechnology products. J Pharm Sci. 2004;93(9):2184–204.
41. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of
extracellular circulating microRNA. Nucleic Acids Res. 2011;39(16):7223–33.
42. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS,
Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL. Argonaute2 complexes
carry a population of circulating microRNAs independent of vesicles in
human plasma. Proc Natl Acad Sci U S A. 2011;108(12):5003–8.
43. Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, Wang J, Rajewsky N,
Bender TP, Rajewsky K. MiR-150 controls B cell differentiation by targeting
the transcription factor c-Myb. Cell. 2007;131(1):146–59.
44. Lin YC, Kuo MW, Yu J, Kuo HH, Lin RJ, Lo WL, Yu AL. c-Myb is an
evolutionary conserved miR-150 target and miR-150/c-Myb interaction is
important for embryonic development. Mol Biol Evol.
2008;25(10):2189–98.
45. Adams BD, Guo S, Bai H, Guo Y, Megyola CM, Cheng J, Heydari K, Xiao C,
Reddy EP, Lu J. An in vivo functional screen uncovers miR-150-mediated
regulation of hematopoietic injury response. Cell Rep. 2012;2(4):1048–60.
Dinh et al. Radiation Oncology  (2016) 11:61 Page 10 of 11
46. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall
WS, Hill JA, Olson EN. Dysregulation of microRNAs after myocardial
infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S
A. 2008;105(35):13027–32.
47. Xiao J, Meng XM, Huang XR, Chung AC, Feng YL, Hui DS, Yu CM, Sung JJ,
Lan HY. miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice.
Mol Ther.
2012;20(6):1251–60.
48. Qin W, Chung AC, Huang XR, Meng XM, Hui DS, Yu CM, Sung JJ, Lan HY.
TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J
Am Soc Nephrol. 2011;22(8):1462–74.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Dinh et al. Radiation Oncology  (2016) 11:61 Page 11 of 11
